Compugen (CGEN) 24th Annual Needham Virtual Healthcare Conference summary

Company overview and platform

• Focuses on immuno-oncology using a proprietary computational platform, Unigen, to discover novel drug targets validated through pharma partnerships and clinical progress.

• Pipeline includes two fully owned assets (COM701, COM902) and several undisclosed early-stage assets, with a cash runway into 2027.

• Unigen leverages AI and advanced sequencing collaborations (e.g., with Ultima Genomics) to identify and validate new immune-oncology targets.

Pipeline highlights and clinical strategy

• COM701, a first-in-class anti-PVRIG antibody, demonstrated differentiated activity and safety in platinum-resistant ovarian cancer, prompting a move to earlier, platinum-sensitive maintenance settings.

• Adaptive trial for COM701 in platinum-sensitive ovarian cancer starts Q2 2024, with results expected in H2 2026; aims to extend progression-free survival by three months.

• COM902, a best-in-class anti-TIGIT antibody with reduced FC receptor binding, is positioned for improved safety and efficacy, with ongoing Phase 3 trials via AstraZeneca partnership.

• AstraZeneca’s TIGIT PD-1 bispecific (rilvegostomig) is in multiple Phase 3 studies, with potential blockbuster sales and milestone/royalty opportunities.

Collaborations and financials

• Gilead collaboration on a novel cytokine-targeting antibody (GS-0321) yielded $90 million to date, with up to $758 million in milestones and double-digit royalties; Compugen leads early clinical development.

• AstraZeneca partnership on TIGIT assets has delivered $30 million in milestones, with eligibility for $170 million more and mid-single-digit royalties.

• Ongoing collaborations, such as with Ultima Genomics, enhance the company’s AI-driven discovery capabilities and feed the clinical pipeline.